Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 agonist
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Evidence
Strong
FDA status
FDA-approved
Source
Synthetic GLP-1 receptor agonist
Overview
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Mechanism of Action
Binds GLP-1 receptors in pancreas and brain, increases insulin secretion and decreases glucagon, slows gastric emptying for prolonged satiety, acts on hypothalamic appetite centers to reduce food intake, 94% homology to native GLP-1 with modifications for extended half-life (7 days).
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Weight loss (STEP trials)
- Improved glycemic control in diabetes
- Reduced appetite and cravings
- Lower risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight (Wegovy)
- Lower HbA1c
- Slower kidney disease worsening in type 2 diabetes with chronic kidney disease (Ozempic)
Researched for
Includes FDA-approved uses where marked; other items are research topics, not approved uses.
How Gabriel approaches peptides
Semaglutide can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.
Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.
Research & Evidence
Multiple large RCTs (STEP, SUSTAIN trials), FDA approved
Large randomized trials (STEP, SUSTAIN, SELECT, FLOW, ESSENCE) support its FDA-approved uses: type 2 diabetes, chronic weight management, lowering cardiovascular risk in adults with heart disease and obesity or overweight (2024), kidney disease in type 2 diabetes (2025) and MASH with moderate-to-advanced fibrosis (accelerated approval, 2025).
Safety Information
Potential Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Risk of pancreatitis
- •Gallbladder disease
Contraindications
- Medullary thyroid carcinoma history
- MEN 2 syndrome
- Pregnancy
- Breastfeeding
- Pancreatitis history
Interactions
- ⚠Delays gastric emptying (affects oral medication absorption)
- ⚠May potentiate insulin/sulfonylureas
Quick Facts
Related Peptides
AOD-9604
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Tirzepatide
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.
Retatrutide
Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.